bioRxivBiochemistryPreprint
A Minimal Synthetic Cleavage Module Enables Selective Degradation of Pathogenic r(CUG) Repeats in Cells
Jingsong ShaniD, Sandra KovachkaiD, Kisu SungiD, Matthew David DisneyiD
Abstract
Although direct RNA degradation offers an alternative to occupancy-driven activity, it has relied on complex natural product-derived cleavage modules such as bleomycin. Here, we show that a compact synthetic Fe(II)-coordinating warhead can be programmed for selective RNA degradation in cells. Coupling this cleavage module to a small molecule that recognizes expanded r(CUG) repeats that cause myotonic dystrophy type 1 (DM1) afforded selective degradation of the pathogenic RNA while sparing wild type and transcripts harboring short r(CUG) repeats. In DM1 patient-derived myoblasts, degradation of mutant repeat RNA reduced DM1-associated pathology including formation of nuclear foci, sequestration of MBNL1, and alternative pre-mRNA splicing defects, without inducing DNA damage. These studies establish that minimal synthetic cleavage modules can replace complex natural product warheads to enable selective degradation of disease-causing RNAs in cells.
- organism: human
- assay: multiome
- assay: proteomics
- assay: metagenomics
- research focus: host-pathogen & immune response
- research focus: differential expression
- research focus: cell type annotation
- research focus: drug response / drug discovery
- approach: experimental assay
- approach: wet-lab / biochemical assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A Toxic RNA Catalyzes the Cellular Synthesis of Its Own Inhibitor, Shunting It to Endogenous Decay Pathways
Raphael I. Benhamou, Alicia J. Angelbello, … Matthew David Disney·Cell chemical biologyPeer-reviewed·Jan 24, 2020
- A small molecule that binds an RNA repeat expansion stimulates its decay via the exosome complex
A. J. Angelbello, R. I. Benhamou, … M. D. Disney·bioRxiv·May 11, 2020
- Treating Myotonic Dystrophy with artificial RNA endonucleases to specifically degrade toxic RNA expansions
Tong Wei, Hanyang Hu, … Zefeng Wang·bioRxiv·Jun 10, 2025
- Targeting Toxic Nuclear RNA Foci with CRISPR-Cas13 to Treat Myotonic Dystrophy
Pornthida Poosala, Sean R. Lindley, … Douglas M. Anderson·bioRxiv·Jul 26, 2019
- Engineered bacterial M1GS ribozyme efficiently cleaves the most abundant ribosomal RNA in a human cancer cell line
Neha Priyadarshini, Navinchandra Venkatarama Puppala, … Gireesha Mohannath·bioRxiv·Nov 7, 2025
- Reversal of molecular pathology by RNA-targeting Cas9 in a myotonic dystrophy mouse model
Ranjan Batra, David A. Nelles, … Gene Wei-Ming Yeo·bioRxiv·Sep 4, 2017